Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 17Carcinoma 5Neoplasm Metastasis 3Colonic Neoplasms 3Brain Neoplasms 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vipoma 1Recurrence 1Neuroendocrine Tumors 1Meningeal Carcinomatosis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms, Male 1Advanced Malignancies 1

Interventions

Paclitaxel 114Carboplatin 114Cisplatin 45Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28liposomal doxorubicin 27Bevacizumab 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15sargramostim 12Hyperthermic Intraperitoneal Chemotherapy 12olaparib 11Chemotherapy, Adjuvant 10Surgical Procedures, Operative 9Etoposide 9oregovomab 8mirvetuximab soravtansine 8Nivolumab 8Amifostine 8Therapeutics 7Melphalan 7Erlotinib Hydrochloride 7rucaparib 6aldesleukin 6Oxaliplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ovarian Epithelial × epothilone B × Clear all
NCT00262990 2020-12-17

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Novartis

Phase 3 Completed
829 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡